Please use this identifier to cite or link to this item:
|Title:||Pharmacotherapy of obsessive-compulsive disorder||Authors:||Ko, S.-M.||Issue Date:||1995||Citation:||Ko, S.-M. (1995). Pharmacotherapy of obsessive-compulsive disorder. British Journal of Clinical Practice 49 (1) : 36-39. ScholarBank@NUS Repository.||Abstract:||Previously thought of as merely an interesting syndrome, obsessive-compulsive disorder is now estimated to afflict 1%-2% of the world's population. Over the past decade extensive research into the epidemiology, aetiology, pathophysiology and pharmacological treatment of this condition has greatly improved its prognosis. This is largely due to the development of the serotonergic group of antidepressants, the selective serotonin reuptake inhibitors (SSRIs), which have consistently demonstrated antiobsessional properties. Monoamine oxidase inhibitors (MAOIs) and lithium have also contributed to the amelioration of symptoms in some patients. Other pharmacological treatment, often prescribed in combination with the SSRIs, include the antipsychotic drugs, benzodiazepines, and anticonvulsants.||Source Title:||British Journal of Clinical Practice||URI:||http://scholarbank.nus.edu.sg/handle/10635/131684||ISSN:||00070947|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 22, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.